Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs

Phosphoinositide 3-kinase δ (PI3Kδ) has a key role in lymphocytes, and inhibitors that target this PI3K have been approved for treatment of B cell malignancies(1–3). Although studies in mouse models of solid tumours have demonstrated that PI3Kδ inhibitors (PI3Kδi) can induce anti-tumour immunity(4,5...

Descripción completa

Detalles Bibliográficos
Autores principales: Eschweiler, Simon, Ramírez-Suástegui, Ciro, Li, Yingcong, King, Emma, Chudley, Lindsey, Thomas, Jaya, Wood, Oliver, von Witzleben, Adrian, Jeffrey, Danielle, McCann, Katy, Simon, Hayley, Mondal, Monalisa, Wang, Alice, Dicker, Martina, Lopez-Guadamillas, Elena, Chou, Ting-Fang, Dobbs, Nicola A., Essame, Louisa, Acton, Gary, Kelly, Fiona, Halbert, Gavin, Sacco, Joseph J., Schache, Andrew Graeme, Shaw, Richard, McCaul, James Anthony, Paterson, Claire, Davies, Joseph H., Brennan, Peter A., Singh, Rabindra P., Loadman, Paul M., Wilson, William, Hackshaw, Allan, Seumois, Gregory, Okkenhaug, Klaus, Thomas, Gareth J., Jones, Terry M., Ay, Ferhat, Friberg, Greg, Kronenberg, Mitchell, Vanhaesebroeck, Bart, Vijayanand, Pandurangan, Ottensmeier, Christian H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132770/
https://www.ncbi.nlm.nih.gov/pubmed/35508656
http://dx.doi.org/10.1038/s41586-022-04685-2

Ejemplares similares

Ejemplares similares